Clinical experience of effective use of palliative targeted therapy in a patient with EGFR-negative lung adenocarcinoma
The article describes the experience in effective use of the second-generation EGFR II blocker in palliative target therapy of EGFRnegative lung adenocarcinoma. The use of afatinib in the fifth-line palliative therapy of EGFR-negative lung adenocarcinoma allowed us to achieve a significant positive...
Main Authors: | L. M. Kogonia, E. V. Markarova, G. A. Stashuk, M. M. Byakhova, M. M. Akhmetov |
---|---|
Format: | Article |
Language: | Russian |
Published: |
Remedium Group LLC
2019-06-01
|
Series: | Медицинский совет |
Subjects: | |
Online Access: | https://www.med-sovet.pro/jour/article/view/3065 |
Similar Items
-
Nomogram based on preoperative CT imaging predicts the EGFR mutation status in lung adenocarcinoma
by: Guojin Zhang, et al.
Published: (2021-01-01) -
Lung Adenocarcinoma with Pulmonary Miliary Metastases and Complex Somatic Heterozygous EGFR Mutation
by: Alexandre Schaller, et al.
Published: (2014-11-01) -
Erlotinib in combined therapy of common lung adenocarcinoma in the presence of EGFR gene mutation
by: S. V. Orlov, et al.
Published: (2019-06-01) -
Transformation or tumor heterogeneity: Mutations in EGFR, SOX2, TP53, and RB1 persist in the histological rapid conversion from lung adenocarcinoma to small‐cell lung cancer
by: Lidan Hao, et al.
Published: (2023-04-01) -
AFATINIB IN THE TREATMENT OF METASTATIC AND LOCALLY ADVANCED LUNG ADENOCARCINOMA WITH EGFR MUTATIONS: NEW SIDES STUDIED POSSIBILITIES
by: E. V. Karabina, et al.
Published: (2017-11-01)